TITLE

OSI INITIATES PHASE I CLINICAL TRIAL OF PSN357

PUB. DATE
September 2005
SOURCE
Worldwide Biotech;Sep2005, Vol. 17 Issue 9, p4
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the phase one clinical study initiated by OSI Pharmaceuticals for PSN357, a glycogen phosphorylase inhibitor (GPI). Science behind the research efforts of OSI in diabetes; Target healthy volunteers for the study; Factor that contributes to hyperglycemia in type two diabetes.
ACCESSION #
18070179

 

Related Articles

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics